Patent ID: 7019016

Claim:
A method of treating Restless Leg Syndrome in a mammal, wherein the method comprises administering to the mammal an amount of an NR2B subunit selective NMDA antagonist, wherein the amount is effective in treating Restless Leg Syndrome, wherein the NR2B subunit selective NMDA receptor antagonist is a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein: (a) R 2 and R 5 are taken separately and R 1 , R 2 , R 3 and R 4 are each independently hydrogen, (C 1 -C 6 ) alkyl, halo, CF 3 , OH or OR 7 and R 5 is methyl or ethyl; or, (b) R 2 and R 5 are taken together and are forming a chroman-4-ol ring, and R 1 , R 3 and R 4 are each independently hydrogen, (C 1 -C 6 ) alkyl, halo, CF 3 , OH or OR 7 ; R 6 is R 7 is methyl, ethyl, isopropyl or n-propyl; R 8 is phenyl optionally substituted with up to three substituents independently selected from the group consisting of (C 1 -C 6 ) alkyl, halo and CF 3 ; X is 0, S or (CH 2 ) n ; and n is 0, 1, 2, or 3.